Rare Disease Genetic Testing
SKU
MRR-B9334AD6C623
Region
Global
Publication Date
January 2024
Delivery
Immediate
2022
USD 1.15 billion
2030
USD 3.80 billion
2023
USD 1.33 billion
CAGR
16.06%
Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2023-2030

[185 Pages Report] The Rare Disease Genetic Testing Market size was estimated at USD 1.15 billion in 2022 and expected to reach USD 1.33 billion in 2023, at a CAGR 16.06% to reach USD 3.80 billion by 2030.

Rare Disease Genetic Testing Market
To learn more about this report, request a free sample copy

Rare disease genetic testing refers to the process of analyzing DNA, RNA, chromosomes, proteins, or certain metabolites to identify genetic mutations or abnormalities that may lead to a rare disease. Since rare diseases are predominantly genetic in origin, such tests are pivotal for early and accurate diagnosis. Advances in genomic technologies have significantly reduced the cost and increased the speed and accuracy of genetic tests. Moreover, there is a growing awareness and understanding of the importance of early and precise diagnosis in managing rare diseases, which has led to a rise in demand for these tests. However, the possibility of uncertain or ambiguous results and issues related to privacy, and the potential for genetic discrimination impact the utility of genetic testing. To address these issues, stringent guidelines and regulations must be enforced to ensure the privacy and ethical conduct of genetic testing. With ongoing scientific advancements, the development of more sophisticated and comprehensive testing methods, such as next-generation sequencing, is on the horizon. Additionally, there is an increasing trend toward consumer-driven healthcare, which may bolster the market for direct-to-consumer genetic testing kits.

Rare Disease Genetic Testing Market - Global Forecast 2023-2030
To learn more about this report, request a free sample copy
Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases

Genetic tests for rare cancers can identify hereditary or somatic mutations that drive tumorigenesis. Such tests are critical for personalized medicine approaches, as they can inform targeted therapies. Genetic testing for cardiovascular disorders can pinpoint mutations that contribute to conditions such as cardiomyopathies and arrhythmias, which have significant implications for patient management and family screening. Rare genetic skin diseases, such as epidermolysis bullosa, have been the focus of genetic diagnostic tests to help with management and potential gene therapy. Conditions such as congenital adrenal hyperplasia and phenylketonuria require genetic testing to confirm diagnoses and enable dietary and medical interventions. Genetic tests for rare hematological conditions, namely hemophilia and sickle cell disease, are valuable for treatment decisions, prognosis, and genetic counseling. Immunological disorders such as primary immunodeficiencies where genetic testing can determine specific immune dysfunctions to guide appropriate treatments. Rare genetic disorders affecting the musculoskeletal system, including Duchenne Muscular Dystrophy, benefit from genetic testing for early intervention and genetic counseling. Genetic tests for disorders such as Huntington's disease and various ataxias are essential for prognosis, symptomatic treatment plans, and reproductive decisions.

End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes

Diagnostic laboratories play a pivotal role in the rare disease genetic testing market as a primary setting for conducting genetic analyses. The need-based preference for diagnostic laboratories arises from their expertise in providing comprehensive genetic testing services, which are essential for accurate diagnosis and guiding treatment plans. These laboratories are well-equipped with advanced technologies capable of performing a wide array of genetic assays, from sequencing to gene panels. Hospitals and clinics represent another critical end-user of rare disease genetic testing, offering direct patient care and diagnosis. These settings prioritize genetic testing services that integrate seamlessly with patient management and allow for multidisciplinary approaches to care. Research laboratories and contract research organizations (CROs) are specialized end-users whose preference for rare disease genetic testing is driven by the need to support research initiatives or drug development. These settings use genetic testing for understanding disease pathology, identifying biomarkers, and advancing clinical trials.

Regional Insights

The Americas exhibit a robust genetic testing infrastructure and a high awareness level among healthcare providers and patients, bolstered by a strong presence of leading companies and supportive regulatory frameworks. Reimbursement policies and investments in rare disease research contribute to the widespread use and production of genetic tests. The APAC region, while rapidly growing, reveals disparities in access and adoption of rare disease genetic testing. Japan and Australia lead with advancements in technology and increasing government support. Collaborations with global entities shape the production and use in this region, and a growing number of local players are investing in R&D. Meanwhile, the EMEA region presents a diverse landscape; Western Europe mirrors the Americas in terms of technology adoption and production capabilities, with well-established companies driving growth. The EU's regulations, including GDPR, impact genetic data usage, having both positive and negative implications on the market. The Middle East and Africa are nascent markets where awareness is gradually increasing. Genetic testing in these areas is sporadically utilized, primarily facilitated by international aid and partnerships. Companies range from large multinational diagnostics firms to specialized biotechs focused on rare disease genetics in this region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Rare Disease Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Rare Disease Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Burjeel Holdings To Launch Rare Disease Research & Development Project ‘Nader’ In Partnership With US-Based Bridgebio Pharma

    Burjeel Holdings and BridgeBio Pharma, a biopharmaceutical company dedicated to the discovery of treatments for genetic diseases and cancers, have forged a partnership through a preliminary Collaboration Agreement to initiate project 'NADER'—a pioneering initiative in the United Arab Emirates. This project, whose name means 'rare' in Arabic, is set to transform early detection and therapy for rare, often genetic disorders that are typically life-long and may be life-threatening or debilitating. [Published On: 2023-12-07]

  • NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues

    The National Institutes of Health announced the inception of the Common Fund’s Somatic Mosaicism Across Human Tissues (SMaHT) Network. This innovative initiative is dedicated to advancing our understanding of the extent of genetic variation across various human tissues. The program is positioned to engender a paradigm shift in the detection and treatment of rare genetic disorders, by enabling a deeper insight into the genetic diversity within individuals. [Published On: 2023-05-11]

  • CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

    Centogene N.V., a partner for data-driven solutions in rare and neurodegenerative disorders, unveiled its pioneering NEXT CentoGenome assay, an enhanced whole genome sequencing (WGS) tool. Its novel design excludes Polymerase Chain Reaction (PCR), mitigating typical biases and resulting in enriched sequencing data. NEW CentoGenome propels the quest for thorough diagnosis and personalized treatment strategies with unparalleled sensitivity and coverage, marking a significant stride in the landscape of genetic healthcare. [Published On: 2023-04-12]

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include 3billion, Inc., Ambry Genetics Corporation, Arup Laboratories, Baylor Genetics, Biora Therapeutics, Inc., Blueprint Genetics Oy, Caris Life Sciences, Centogene N.V., Color Health, Inc., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., GeneDx, LLC, Genomelink, Inc., Helix OpCo, LLC, Illumina, Inc., Integrated DNA Technologies, Inc. by Danaher Corporation, Invitae Corporation, Laboratory Corporation Of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., Nonacus Limited, OPKO Health, Inc., PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Realm IDX, Inc., Sanofi S.A., The Cooper Companies, Inc., Thermo Fisher Scientific Inc., and Variantyx, Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Cancer
    • Cardiovascular Disorders
    • Dermatology Diseases
    • Endocrine & Metabolism Diseases
    • Hematology Diseases
    • Immunological Disorders
    • Musculoskeletal Disorders
    • Neurological Disorders
  • Technology
    • Array Technology
    • FISH
    • Karyotyping
    • Next Generation Sequencing
      • Whole Exome Sequencing
      • Whole Genome Sequencing
    • PCR - Based Testing
    • Sanger Sequencing
  • Specialty
    • Biochemical Genetic Tests
    • Chromosomal Genetic Tests
    • Molecular Genetic Tests
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research Laboratories & CROs

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Rare Disease Genetic Testing Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Rare Disease Genetic Testing Market?
  3. What are the technology trends and regulatory frameworks in the Rare Disease Genetic Testing Market?
  4. What is the market share of the leading vendors in the Rare Disease Genetic Testing Market?
  5. Which modes and strategic moves are suitable for entering the Rare Disease Genetic Testing Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoverageRARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. RARE DISEASE GENETIC TESTING MARKET SIZE, 2022 VS 2030
  4. Market Overview
    1. IntroductionRARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
    2. Rare Disease Genetic Testing Market, by RegionRARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2022 VS 2030 (%)RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsRARE DISEASE GENETIC TESTING MARKET DYNAMICS
      1. Drivers
        1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
        2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
        3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
      2. Restraints
        1. Ethical Concerns and Access to Limited Information on Rare Disease
      3. Opportunities
        1. Advancements in Genetic Technology to Identify New Rare Disease Genes
        2. Favorable Investments for Diagnosis of Rare Genetic Diseases
      4. Challenges
        1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
    2. Market Segmentation Analysis
      1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
      2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
    3. Market Trend Analysis
    4. Cumulative Impact of COVID-19
    5. Cumulative Impact of Russia-Ukraine Conflict
    6. Cumulative Impact of High Inflation
    7. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    8. Value Chain & Critical Path Analysis
    9. Regulatory Framework
    10. Client Customization
  6. Rare Disease Genetic Testing Market, by Disease Type
    1. IntroductionRARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
    2. CancerRARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY , 2018-2030 (USD MILLION)
    3. Cardiovascular DisordersRARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY , 2018-2030 (USD MILLION)
    4. Dermatology DiseasesRARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY , 2018-2030 (USD MILLION)
    5. Endocrine & Metabolism DiseasesRARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY , 2018-2030 (USD MILLION)
    6. Hematology DiseasesRARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY , 2018-2030 (USD MILLION)
    7. Immunological DisordersRARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY , 2018-2030 (USD MILLION)
    8. Musculoskeletal DisordersRARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY , 2018-2030 (USD MILLION)
    9. Neurological DisordersRARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY , 2018-2030 (USD MILLION)
  7. Rare Disease Genetic Testing Market, by Technology
    1. IntroductionRARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
    2. Array TechnologyRARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY , 2018-2030 (USD MILLION)
    3. FISHRARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY , 2018-2030 (USD MILLION)
    4. KaryotypingRARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY , 2018-2030 (USD MILLION)
    5. Next Generation SequencingRARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY , 2018-2030 (USD MILLION)
    6. RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
      1. Whole Exome SequencingRARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY , 2018-2030 (USD MILLION)
      2. Whole Genome SequencingRARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY , 2018-2030 (USD MILLION)
    7. PCR - Based TestingRARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY , 2018-2030 (USD MILLION)
    8. Sanger SequencingRARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY , 2018-2030 (USD MILLION)
  8. Rare Disease Genetic Testing Market, by Specialty
    1. IntroductionRARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2022 VS 2030 (%)RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2022 VS 2023 VS 2030 (USD MILLION)RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
    2. Biochemical Genetic TestsRARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY , 2018-2030 (USD MILLION)
    3. Chromosomal Genetic TestsRARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY , 2018-2030 (USD MILLION)
    4. Molecular Genetic TestsRARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY , 2018-2030 (USD MILLION)
  9. Rare Disease Genetic Testing Market, by End-User
    1. IntroductionRARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2022 VS 2030 (%)RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    2. Diagnostic LaboratoriesRARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY , 2018-2030 (USD MILLION)
    3. Hospitals & ClinicsRARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY , 2018-2030 (USD MILLION)
    4. Research Laboratories & CROsRARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY , 2018-2030 (USD MILLION)
  10. Americas Rare Disease Genetic Testing Market
    1. Introduction
    2. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    3. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    14. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2022 VS 2030 (%)UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  11. Asia-Pacific Rare Disease Genetic Testing Market
    1. Introduction
    2. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    6. China
    7. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    8. India
    9. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  12. Europe, Middle East & Africa Rare Disease Genetic Testing Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  13. Competitive Landscape
    1. FPNV Positioning MatrixRARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2022RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2022
    2. Market Share Analysis, By Key PlayerRARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2022RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2022
    3. Competitive Scenario Analysis, By Key Player
      1. Burjeel Holdings To Launch Rare Disease Research & Development Project ‘Nader’ In Partnership With US-Based Bridgebio Pharma
      2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
      3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
  14. Competitive Portfolio
    1. Key Company Profiles
      1. 3billion, Inc.
      2. Ambry Genetics Corporation
      3. Arup Laboratories
      4. Baylor Genetics
      5. Biora Therapeutics, Inc.
      6. Blueprint Genetics Oy
      7. Caris Life Sciences
      8. Centogene N.V.
      9. Color Health, Inc.
      10. F. Hoffmann-La Roche Ltd.
      11. Fulgent Genetics, Inc.
      12. GeneDx, LLC
      13. Genomelink, Inc.
      14. Helix OpCo, LLC
      15. Illumina, Inc.
      16. Integrated DNA Technologies, Inc. by Danaher Corporation
      17. Invitae Corporation
      18. Laboratory Corporation Of America Holdings
      19. Macrogen, Inc.
      20. Myriad Genetics, Inc.
      21. Nonacus Limited
      22. OPKO Health, Inc.
      23. PerkinElmer Inc.
      24. QIAGEN N.V.
      25. Quest Diagnostics Incorporated
      26. Realm IDX, Inc.
      27. Sanofi S.A.
      28. The Cooper Companies, Inc.
      29. Thermo Fisher Scientific Inc.
      30. Variantyx, Inc.
    2. Key Product Portfolio
  1. 3billion, Inc.
  2. Ambry Genetics Corporation
  3. Arup Laboratories
  4. Baylor Genetics
  5. Biora Therapeutics, Inc.
  6. Blueprint Genetics Oy
  7. Caris Life Sciences
  8. Centogene N.V.
  9. Color Health, Inc.
  10. F. Hoffmann-La Roche Ltd.
  11. Fulgent Genetics, Inc.
  12. GeneDx, LLC
  13. Genomelink, Inc.
  14. Helix OpCo, LLC
  15. Illumina, Inc.
  16. Integrated DNA Technologies, Inc. by Danaher Corporation
  17. Invitae Corporation
  18. Laboratory Corporation Of America Holdings
  19. Macrogen, Inc.
  20. Myriad Genetics, Inc.
  21. Nonacus Limited
  22. OPKO Health, Inc.
  23. PerkinElmer Inc.
  24. QIAGEN N.V.
  25. Quest Diagnostics Incorporated
  26. Realm IDX, Inc.
  27. Sanofi S.A.
  28. The Cooper Companies, Inc.
  29. Thermo Fisher Scientific Inc.
  30. Variantyx, Inc.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Rare Disease Genetic Testing Market
The Global Rare Disease Genetic Testing Market size was estimated at USD 1.15 billion in 2022 and expected to reach USD 1.33 billion in 2023.
The Global Rare Disease Genetic Testing Market to grow USD 3.80 billion by 2030, at a CAGR of 16.06%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.